Drugs / Oanzapine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00857818 Comparator | Apr 2009 → Mar 2010 | bipolar I disorder, metabolic syndrome X, schizoaffective disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oanzapine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00857818 ↗ |
| Route | Oral | “Oanzapine, risperidone, or quetiapine administered orally as tablets” NCT00857818 ↗ |